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Abstract
Background: The world is currently confronting the first influenza pandemic of the 21
st century. Influenza vaccination is an
effective preventive measure, but the unique epidemiological features of swine-origin influenza A (H1N1) (pH1N1) introduce
uncertainty as to the best strategy for prioritization of vaccine allocation. We sought to determine optimal prioritization of
vaccine distribution among different age and risk groups within the Canadian population, to minimize influenza-
attributable morbidity and mortality.
Methodology/Principal Findings: We developed a deterministic, age-structured compartmental model of influenza
transmission, with key parameter values estimated from data collected during the initial phase of the epidemic in Ontario,
Canada. We examined the effect of different vaccination strategies on attack rates, hospitalizations, intensive care unit
admissions, and mortality. In all scenarios, prioritization of high-risk individuals (those with underlying chronic conditions
and pregnant women), regardless of age, markedly decreased the frequency of severe outcomes. When individuals with
underlying medical conditions were not prioritized and an age group-based approach was used, preferential vaccination of
age groups at increased risk of severe outcomes following infection generally resulted in decreased mortality compared to
targeting vaccine to age groups with higher transmission, at a cost of higher population-level attack rates. All simulations
were sensitive to the timing of the epidemic peak in relation to vaccine availability, with vaccination having the greatest
impact when it was implemented well in advance of the epidemic peak.
Conclusions/Significance: Our model simulations suggest that vaccine should be allocated to high-risk groups, regardless of
age, followed by age groups at increased risk of severe outcomes. Vaccination may significantly reduce influenza-attributable
morbidityand mortality, butthe benefits aredependent onepidemic dynamics,time forprogramroll-out,and vaccine uptake.
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Introduction
The rapid global spread of a novel swine-origin influenza A
(H1N1) (pH1N1) virus led the World Health Organization to
declare an influenza pandemic on June 11, 2009 [1]. When there
is a good match between circulating and vaccine strains, influenza
immunization is the most effective preventive measure for
reducing influenza-related morbidity and mortality [2]. Develop-
ment of a vaccine against pH1N1 began in the early phases of the
epidemic, leading to questions about prioritization of vaccine
allocation within populations, given that not all vaccine would be
distributed at once (due to production and logistical constraints).
Seasonal influenza immunization campaigns typically target the
elderly and those of any age with one or more underlying medical
conditions, under the assumption that it is best to protect those
most likely to have complications from influenza. Recently, there
has been debate over whether this is the best approach [3,4]. The
degree of protection conferred by the influenza vaccine appears to
be lower in the elderly than in the general population [5] and it
has been suggested that an immunization strategy based on
reducing transmission would have a greater impact on reducing
overall disease burden than the current practice of focusing
vaccination efforts on at-risk groups [6]. In particular, the
potential benefit of preferentially vaccinating school-aged children
has been discussed, since this age group is disproportionately
responsible for influenza transmission [7,8,9].
As with earlier pandemics, pH1N1 is characterized by age
distributions that are distinct from those observed in seasonal
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10520influenza epidemics, with higher attack rates and increased
proportionate mortality, in younger individuals [10,11,12]. This
differential vulnerability to infection by age will have important
implications for the choice of optimal vaccination strategies [13].
Given the uncertainty surrounding optimal vaccine allocation
strategies and the unique epidemiological characteristics of
pH1N1, we sought to determine optimal prioritization of vaccine
distribution among different age groups in order to minimize
influenza-attributable morbidity and mortality in the Canadian
population. To address this question we developed an age-
structured mathematical model to describe expected pH1N1
transmission during the 2009–2010 influenza season. We used this
model to evaluate the optimal sequencing of vaccination allocation
strategies. Each strategy was tested using different assumptions
relating to pre-existing immunity, vaccination coverage, and the
timing of the epidemic peak. The outcomes of interest were
influenza-attributable morbidity and mortality under different
vaccination strategies.
Methods
Model structure
We developed a deterministic, age-structured compartmental
model of influenza transmission in the Canadian population (see
Figure 1 for overall structure and File S1 for additional model
details). The model ran from mid-April, 2009 (the date of the first
identified cases of pH1N1 in Ontario, Canada) to June 30, 2010,
representing a single influenza season. As a result, we did not
consider waning immunity following infection or vaccination,
migration into or out of the population, or population aging.
The population was divided into four compartments represent-
ing different disease states: susceptible (S), exposed (E; i.e., infected
but not infectious), infectious (I), and recovered (R). Transmission
of infection occurred through contact between susceptible and
infectious individuals. We assumed that 40% of infections were
asymptomatic [14], but did not consider differential transmission
in symptomatic versus asymptomatic cases.
Age structure and mixing patterns
To explore how vaccination of different age groups would
impact overall influenza morbidity and mortality and to enable the
representation of more realistic contact patterns within and
between age groups, we included age stratification. The
population was divided into seven age classes with the following
cutoffs: 0–4, 5–13, 14–17, 18–22, 23–52, 53–64 and $65.
Demographic information was obtained from 2006 Canadian
census data [15]. We included the 53–64 year old age category to
model the decreased susceptibility observed in persons born prior
to the 1957 pandemic [12,16,17] and divided the younger ages
according to school groupings to allow for the modeling of school-
based vaccination programs. Mixing within and between age
strata was based on a population-based prospective study of
contact patterns in eight European countries [18].
For a subset of model scenarios, each age class was further
subdivided into two states: healthy or underlying chronic medical
condition for which seasonal influenza immunization is recom-
mended. Transitions between model compartments were identical
for individuals in the healthy or chronic condition states, but
probabilities of experiencing severe clinical outcomes were
different. We included a separate pregnancy state, representing
women in the second or third trimester of pregnancy, with the
number of women expected to be in this state at any given point in
time derived using annual estimates of pregnancies and live births
in Canada (see File S1 for further details) [19,20].
Pre-existing immunity
To reflect the presence of immunity due to previous exposure to
related influenza strains among individuals aged 53 and over,
resistance to pH1N1 was modeled by moving some individuals
from the susceptible to the resistant compartment at time zero.
Since it is currently clinically impractical to distinguish individuals
with pre-existing exposure to the circulating strains, we assumed
that they received the same vaccination coverage as the susceptible
population (i.e. there was no way to preferentially immunize the
truly susceptible population).
Vaccination
Vaccination with two doses of H1N1 vaccine was modeled by
removing a select number of individuals from the susceptible
compartment immediately following administration of the second
dose of vaccine. Vaccination began in mid-November (November
15
th), with a delay of 21 days between administration of the first
and second doses. The fraction of the vaccinated population that
acquired immunity was based on vaccine effectiveness estimates of
70 percent; for a given age group, with a vaccine effectiveness (VE)
and coverage (C), the proportion removed from the susceptible to
the resistant compartment was VE*C. We assumed that this group
was fully protected against infection, with the remaining fraction
VE*(1-C) receiving no protection. Although this does not reflect the
Figure 1. Outline of model structure, showing population flows
between compartments. Each compartment is further stratified by
age category (and by healthy and chronic condition states, where
required).
doi:10.1371/journal.pone.0010520.g001
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some degree of protection, this approach has been used previously
and has been demonstrated to provide a reasonable model of
partial efficacy [21]. We did not consider the effect of partial
protection following the first dose. We assumed that it took four
weeks to administer the first dose of vaccine to all age groups and
vaccine allocation within each targeted sub-group (described
below) occurred simultaneously at the beginning of each week (see
File S1 for additional details on timing of vaccination).
Disease natural history and model parameterization
Model parameters for pH1N1 were based on the initial case
data from the province of Ontario (Table 1) [22]. A range of
estimates of the proportion of the population aged $53 with pre-
existing immunity to pH1N1 influenza was derived from reported
serological data [23], the relative risk of infection by age observed
in Ontario [12] and model calibration to the Ontario epidemic
curve. We considered pre-existing immunity levels of 30, 50, and
70 percent in this segment of the population.
Age-specific hospitalization, ICU admission, and mortality rates
were calculated using data from Ontario’s Integrated Public
Health Information System (iPHIS), which collected information
on all laboratory-confirmed cases of pH1N1 in the province
reported between April 13 and June 21, 2009 (Table 2) [22]. To
account for expected under-ascertainment of less severe cases, we
multiplied the denominator (total cases) by a factor of ten when
calculating hospitalization and case-fatality rates [24].
We used vaccination coverage data for the province of Ontario
[25,26], which operates a universal influenza immunization
program that provides influenza vaccine free of charge to the
entire population aged six months or older, as a base case for H1N1
vaccine uptake (Table 3). Telephone survey data on willingness to
accept pH1N1 vaccine in the province of Ontario obtained using
the province’s Rapid Risk Factor Surveillance System (RRFSS) [27]
was used as an upper bound of vaccine uptake in the Canadian
population (Ruth Sanderson, Ontario Agency for Health Protection
and Promotion, personal communication). Age-specific data on
underlying chronic conditions were obtained from the 2007 cycle of
the Canadian Community Health Survey [25].
To model the impact of assumptions about the dynamics of
pH1N1 transmission over the course of the summer, where typical
influenza seasonality and changes in contact patterns may reduce
the basic reproductive number (R0), we modified R0 to generate
differential timing of the peak of the epidemic curve. We
considered the effect of different vaccination strategies when the
epidemic peak occurred in October (no change in R0 over the
summer), November (R0 decreases but remains above endemic
levels from July to September), December (R0=1 from July to
September), or January (R0=1 from July to October). We also
adjusted R0 to account for different levels of pre-existing immunity
to pH1N1 in the population (i.e., to give the same effective
reproductive number under different immunity assumptions).
Vaccination scenarios
We considered four vaccination strategies. For all scenarios, the
total number of vaccine doses was not a limiting factor; adequate
supply of vaccine was available for all individuals requiring
immunization [28].
(i) Age-attack rate-based strategy (AR): Vaccine distributed first
to age groups with the highest model-predicted attack rates
(order of vaccine allocation by age group: 5–17, 18–52, 0–4,
$53)
(ii) Age-outcome-based strategy (Outcome): Vaccine distributed
first to age groups at the highest risk of a severe outcome,
defined as hospitalization, ICU admission, or death,
following infection with pH1N1, ranked in order of
probability of death, ICU admission, and hospitalization
(order of vaccine allocation by age group: $53, 18–52, 0–4,
5–17).
(iii) and (iv) Risk-based strategy (High risk/AR or High risk/
Outcome): Vaccine preferentially distributed to individuals
of any age with an underlying risk condition (based on
seasonal influenza recommendations [2]) and pregnant
women (in the second or third trimester), followed by an
attack rate- or outcome-based strategy described above (i.e.,
based on age-group ranking) (delayed by one week to allow
for immunization of high-risk individuals first).
Table 1. Model Parameter Values.
Variable Age group Value (range) Source
Total population size all 31,612,905 2006 Census [15]
Latent period (days) all 3.5 Model calibration
Duration of infectiousness (days) all 2.5 Model calibration
Effective reproductive number all 1.3 (1.15–1.31) Model calibration
Proportion of population with pre-existing immunity $53 0.5 (0.3–0.7) MMWR, 2009 [23], Fisman et al., 2009 [12], model calibration
Vaccine effectiveness ,65 0.7 Centers for Disease Control and Prevention, 2008 [48]
$65 0.7 (0.3–0.7)
Proportion of population with high-risk conditions
a 0–4 0.10 Moran et al.,2009 [49];Canadian Community Health Survey,2007 [50]
5–13 0.10
14–17 0.12
18–22 0.11
23–52 0.13
53–64 0.27
$65 0.43
aHigh-risk conditions include one or more of: asthma, emphysema, chronic obstructive pulmonary disease, diabetes, heart disease, cancer, and stroke.
doi:10.1371/journal.pone.0010520.t001
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The model was calibrated to fit the initial epidemic curve
observed in Ontario (by minimizing the sum-of-squares difference
between model projections and the observed epidemic curve).
Data for laboratory-confirmed cases with a reported exposure date
between April 13 and June 1, 2009 were obtained from iPHIS.
Travel history data, including illness on return to Mexico, were
used to model the observed multiple introductions of pH1N1 into
the Ontario population early on in the pandemic.
Sensitivity analyses
We tested the robustness of model projections to baseline
assumptions and parameter values by performing sensitivity analyses,
with model inputs varied over plausible ranges, and incorporating
alternate assumptions regarding vaccine program attributes. We
evaluated the effect on model outputs of changing the time period for
delivery of the first dose of vaccine to the entire population to two or
six weeks, switching to a single vaccine dose, reducing vaccine
effectiveness in the $65 age group (across a range of effectiveness of
30–60 percent), and varying the proportion of asymptomatic cases.
We also assessed the impact of using alternate estimates of
hospitalizations, ICU admissions, and mortality derived from the
U.S. population [29], limiting prioritization of individuals with
underlying medical conditions in the risk-based strategies to those
under 65 yearsof age, and applying a limited vaccine supplyscenario.
Results
Initial epidemic dynamics and model calibration
The model appeared well-calibrated to epidemic curves for
pH1N1 influenza and matched the initial transmission dynamics
observed in Ontario (Figure 2). Figure 3 illustrates the pH1N1
infection dynamicsgeneratedby the model;epidemic curves peaked
in different months, depending on assumptions made about
influenza transmission behaviour during the summer months, but
overall attack rates were consistent across model runs for a given
estimate of pre-existing immunity in the pre-1957 cohort. In the
absence of vaccination, the average infection attack rate across the
entire Canadian population was 35.1% (range 33.2–36.8%). Age-
specific patterns of influenza transmission reflected typical mixing
patterns within a population, with epidemic curves peaking first in
younger age groups, followed by the elderly.
Effect of timing of epidemic peak in relation to vaccine
availability on outcomes
Given the uncertainty around pH1N1 dynamics and timelines
for vaccine delivery, we investigated the impact of the timing of the
epidemic peak on whether an attack rate- or outcome-based
vaccination strategy was preferred (Figure 4). For an October
peak, neither approach was likely to significantly alter outcomes.
For each month that the epidemic was delayed, there was
enhanced effectiveness of all vaccination strategies.
Attack rate-based versus outcome-based vaccination
strategies
We evaluated the percent reduction in predicted attack rates,
number of hospitalizations, ICU admissions, and deaths under
these two strategies, relative to the no intervention scenario
Table 2. Estimated Rates of Hospitalization, ICU Admission, and Mortality by Age and Risk Group for pH1N1 in Ontario, April to
June 2009.
Outcome Age group All
Persons with
high-risk conditions
a
Persons without
high-risk conditions
Hospitalization rate (per 1,000 symptomatic persons)
b 0–4 13.2 22.1 7.5
5–17 2.5 5.1 0.9
18–52 4.3 9.1 1.0
$53 12.9 21.0 8.2
Intensive care unit admission rate (per 1,000 hospitalized
patients)
0–4 0 0 0
5–17 50.0 64.5 0
18–52 196.1 227.3 0
$53 300.0 333.3 250.0
Case-fatality rate (per 1,000 symptomatic persons)
b 0–4 0 0 0
5–17 0.06 0 0.1
18–52 0.25 0.6 0
$53 3.9 5.3 3.1
aHigh-risk conditions include one or more of: asthma, emphysema, chronic obstructive pulmonary disease, diabetes, heart disease, cancer, and stroke.
bDenominators were inflated 10-fold to account for expected underrepresentation of less severe pH1N1 cases among laboratory-confirmed cases.
doi:10.1371/journal.pone.0010520.t002
Table 3. Influenza Vaccination Coverage Levels.
Variable Age group Base case
a Upper bound
b
Proportion vaccinated 0–4 0.26 0.60
5–13 0.30 0.60
14–17 0.31 0.60
18–22 0.29 0.62
23–52 0.29 0.54
53–64 0.47 0.65
$65 0.75 0.75
aSource: Moran et al., 2009 [49]; Kwong et al., 2008 [26].
bSource: RRFSS module (Ontario Ministry of Health and Long-Term Care/Ontario
Agency of Health Protection and Promotion).
doi:10.1371/journal.pone.0010520.t003
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reducing the total number of infections and minimizing hospital-
izations when the epidemic peaked in December or January, with
minimal difference in the impact of competing strategies on overall
attack rates when the epidemic peaked earlier. When there was 30
percent pre-existing immunity in the individuals born prior to
1957 group, there was no preferred strategy for minimizing
hospitalizations. Using ICU admissions as the outcome of interest,
the outcome-based strategy was preferred when there were low
levels of pre-existing immunity, but there was no advantage to
using one strategy over the other when immunity in the older age
groups was $50 percent. By contrast, when mortality was assessed
as the endpoint of interest, an outcome-based strategy was
preferred to an attack rate-based strategy for any combination of
values for pre-existing immunity and vaccine coverage, with the
exception of the assumption of 70 percent immunity to pH1N1 in
individuals aged $53 combined with a January peak. Under this
latter scenario, there was no difference between strategies.
Prioritization of vaccine delivery to individuals with
underlying high-risk conditions (risk-based strategy)
We assessed the effect of preferentially immunizing individuals
of any age with an underlying medical condition (representing
19% of the Canadian population), prior to implementing an attack
rate- or outcome-based strategy. Despite the resulting delay in
vaccine allocation to the remaining population, for all scenarios,
hospitalizations and ICU admissions were reduced compared to
vaccination strategies that did not target high-risk groups
(Figure 5). When the epidemic peak occurred in December or
January, this approach had a less marked effect in reducing
mortality and resulted in higher cumulative attack rates than
strategies that did not prioritize high-risk groups, whereas for an
October or November epidemic peak, this approach had a larger
effect in reducing mortality.
Sensitivity analyses
Increasing the length of time to administer the first vaccine dose
in all age groups from two to six weeks decreased the effectiveness
of vaccination programs when the epidemic peak was in
December or January, but did not have an effect when the peak
occurred earlier (Figure S1).
Reducing vaccine effectiveness in individuals aged $65 did not
have a marked effect on the ranking of vaccination strategies when
levels of pre-existing immunity in the pre-1957 group were 30 or
50 percent. With 70 percent pre-existing immunity and lower
bound vaccination coverage, reducing vaccine effectiveness to 60
Figure 2. Confirmed cases of locally-acquired pH1N1 in Ontario by symptom onset date, April 16–June 1, 2009. Cases that reported a
history of travel to Mexico prior to illness onset are not included. Model-predicted cases assuming 50 percent pre-existing immunity in the $53 age
group, Re of 1.3, latent period of 3.5 days, and duration of infectiousness of 2.5 days are shown (line).
doi:10.1371/journal.pone.0010520.g002
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becoming favoured over outcome-based, when evaluating total
deaths as the outcome of interest. Lowering vaccine effectiveness
did not alter the ranking of the strategies when other outcomes
(ICU admissions, hospitalizations, or attack rate) were the
endpoints of interest.
Increasing the proportion of infectious individuals with
asymptomatic influenza reduced the absolute number of cases
experiencing severe outcomes, but did not change the relative
rankings of the different strategies.
Emerging data suggest that a single dose of vaccine may be
sufficient to confer protective immunity against infection with
pH1N1 [30,31]. When we tested the impact of a single dose on
outcomes, we found no qualitative differences in the rank-order of
vaccination strategies under different conditions for the majority of
scenarios. However, for a January epidemic peak with high
vaccination coverage, the attack rate-based strategy was more
attractive than the outcome-based strategy, regardless of which
endpoint was evaluated (Figure S2).
We considered a modified risk-based strategy, where only
individuals aged less than 65 with underlying medical conditions
were prioritized to receive vaccine (versus individuals of any age
with underlying conditions in the main analysis) prior to
implementing an attack rate- or outcome-based allocation
strategy. For the majority of scenarios, there were no marked
differences in outcomes, suggesting that excluding the $65 age
group from vaccination prioritization schemes would not substan-
tively alter the occurrence of poor outcomes. One notable
exception arose when the epidemic peak occurred in November;
in these scenarios, excluding individuals aged $65 age with
chronic conditions resulted in greater mortality than when all
individuals with chronic conditions were included.
When the total number of vaccine doses was limited to 20% of
the population (enough vaccine to immunize approximately 6
million individuals, with doses divided equally over each week of
vaccination campaign), there was no marked difference in results,
compared to the other vaccination coverages considered, for an
early epidemic peak (Figure S3). In contrast with our main
analysis, an attack rate-based strategy was preferred over an
outcome-based one for all outcomes evaluated when the epidemic
peak occurred later (December or January), relative to when
vaccine became available. For later epidemic peaks, there was no
change in the order of preferred strategies when the risk-based
strategies were evaluated.
The estimated risks of hospitalization, ICU admission, and
mortality were calculated early in the pandemic. To assess the
sensitivity of our results to these values, we repeated our analysis
using more recent estimates derived from the U.S. population
Figure 3. Model-predicted pH1N1 infection dynamics in the absence of vaccination. (A) Simulated age-stratified daily pH1N1 infection
incidence per 100,000 population and (B) age-specific attack rates between April 2009 and June 2010, in the absence of vaccination or other
interventions. Both symptomatic and asymptomatic cases are shown. The curves are based on an assumption of fifty percent pre-existing immunity
in the $53 age group and a decrease in Re from 1.3 to 1.15 between July and September.
doi:10.1371/journal.pone.0010520.g003
Figure 4. Effect of timing of epidemic peak on preferred vaccination strategy. Total model-predicted attack rates and deaths by month of
the pandemic peak are shown, when implementing attack rate (AR)- or outcome-based vaccination strategies. For each month of the epidemic peak,
outcomes are presented for three values of pre-existing immunity among individuals aged $53 (30%, 50%, and 70%) and two vaccination coverage
levels (base case and upper bound). For all scenarios, vaccination campaigns are initiated on November 15, 2009.
doi:10.1371/journal.pone.0010520.g004
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PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10520Figure 5. Impact of vaccination strategy on model outcomes. Percent reduction in attack rate, hospitalizations, ICU admissions, and total
deaths, relative to no vaccination, under different vaccination strategies. The effectiveness of different strategies was evaluated assuming an
epidemic peak in (A) November, 2009 or (B) January, 2010, with vaccination campaigns initiated on November 15, 2009. Results for October, 2009
and December, 2009 were similar to November, 2009 and January, 2010, respectively, and are not shown. The impact of vaccination coverage is also
Pandemic Vaccine Allocation
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using both the upper and lower bound estimates presented by
Presanis and colleagues [29] (see Figure S4 for results using upper
bound estimates, similar patterns were observed using lower
bound estimates, results not shown). Using these rates, vaccine
prioritization preferences are unchanged for an early epidemic
peak. However, for a later epidemic peak, an attack rate-based
strategy resulted in a greater reduction in all outcomes under
consideration, relative to an outcome-based strategy. This
contrasts with our main results, where the preference in strategy
for minimizing ICU admissions and mortality was dependent on
underlying model assumptions. Given the absence of data on the
frequency of occurrence of different outcomes in persons with or
without underlying medical conditions (as defined in our analysis),
we did not include the risk-based strategies in this sensitivity
analysis.
Discussion
We used a mathematical model to evaluate optimal pH1N1
vaccination strategies, focusing our analysis on the Canadian
population and considering the effect of targeting different age
groups for prioritization of vaccine allocation on projected
hospitalizations and mortality. Depending on the outcome
assessed and the assumptions used, both attack rate- and
outcome-based strategies were effective in reducing morbidity
and mortality, but in most scenarios, delaying vaccine distribution
by one week to preferentially immunize individuals with
underlying high-risk conditions was the optimal strategy. We
observed that the dynamics of pH1N1 transmission is a critical
area of uncertainty, with all vaccination strategies having limited
impact if the epidemic peak occurs prior to or concomitantly with
vaccine availability (projected for mid-November in our model).
Our analysis focused on the occurrence of severe outcomes and
did not directly consider the effect of vaccination on reducing
disease transmission and the resultant downstream effects, such as
reduced societal disruption and economic costs (such as those
associated with time lost from work or school). Additionally, when
assessing severe outcomes, there is a need to consider how these
outcomes may interact; for instance, a strategy that focuses on
reducing mortality at the expense of higher attack rates could lead
to the saturation of ICU capacity, resulting in higher mortality in
younger age groups than has been observed to date.
The epidemiology of pH1N1 appears distinct from that of
seasonal influenza (but similar to that of prior pandemics [11,32])
in that younger age is associated with the highest attack rates, a
phenomenon that has resulted in a higher absolute burden of
morbidity and mortality in this age group than is typically
observed with seasonal influenza, even though per-case risks of
poor outcome may not differ from those seen with seasonal
influenza. However, although older age groups are less likely to be
infected with the pandemic strain than younger individuals,
infections in individuals aged .50 years documented in Ontario
have been associated with increased ICU admissions and death
[22].
Several mathematical models have been developed to evaluate
optimal vaccination strategies for pH1N1 [33,34,35,36]. Among
the key findings of these models are: the importance of early
vaccination [36] and the role that prioritizing age groups based on
patterns of severe outcomes can have in mitigating influenza
impact in the population [34,37]. Based on our results, preferential
immunization of children, which has been recommended for both
seasonal [6] and pandemic [33] influenza, and is represented by
the attack rate-based strategy in our model, is the preferred
strategy only when vaccine is available well in advance of the
epidemic peak and its effectiveness is dependent on underlying
model assumptions. By contrast, preferential vaccination of
individuals with underlying medical conditions, regardless of age,
was consistently observed to be an effective strategy to minimize
hospitalizations, ICU admissions, and deaths attributable to
pH1N1. Emerging empirical data from trials using both live
attenuated [38] and inactivated [39] influenza vaccines support
the focus on vaccination of younger individuals as a means to
prevent infection in older individuals. Given that pH1N1 is likely
to be the dominant seasonal strain in coming influenza seasons
and, unlike the pandemic situation, seasonal influenza vaccines are
generally available prior to surges in influenza activity, this
paradigm may have application to near-term seasonal influenza
seasons as well.
Our model assumes that two doses of pH1N1 vaccine will be
required to elicit a protective response, but emerging data have
demonstrated that a single dose may be sufficiently immunogenic
in adults and children [30,31,40]. The implications of a single dose
vaccine are similar to shifting the epidemic peak to later in the
winter, resulting in enhanced effectiveness for any vaccination
strategy adopted, relative to a two-dose schedule. The preference
for an attack rate-based strategy using a single vaccine dose when
vaccination coverage is high agrees with a recent study suggesting
that targeting age groups at the highest risk of infection may be the
optimal solution[33], but in our model, this is only the case when
vaccine is available well before the epidemic peak. Finally, we
evaluated the impact of poor vaccine effectiveness in older
individuals on preferred strategies, as this has been a concern
with seasonal vaccine [41]; we found limited impact of decreased
effectiveness on the rank-ordering of preferred strategies except
when older individuals were highly likely (70%) to be immune to
infection in the absence of vaccination, and were effectively ‘‘pre-
vacccinated’’by early life influenza exposures.
Our analysis is subject to several important limitations. As with
all mathematic models, this model includes simplifying assump-
tions and incorporates parameter values that are subject to some
uncertainty. Model calibration to existing data was used to derive
estimates of key epidemiologic parameters and these values are in
agreement with estimates from other settings [42,43]. We
incorporated non-homogeneous mixing patterns between age
groups, but did not consider the effect of spatial heterogeneity.
However, other studies have demonstrated that estimates of R0
appear to be consistent across locations and spatial scales [44,45].
Some other simplifying assumptions included non-differential
transmissibility of influenza by symptomatic and asymptomatic
cases and non-incorporation of other concurrent mitigation
strategies on influenza transmission, including antivirals and social
distancing measures, on influenza transmission. We also did not
consider the impact of co-circulating seasonal influenza strains,
although recent data suggest that reduced circulation of seasonal
strains may be observed during a pandemic situation [46,47]. To
shown, with base case rates representing the lower bound of vaccine uptake in the Canadian population, compared to likely upper limits of vaccine
uptake. The midpoint of the boxes represents the median percent reduction in the outcome of interest, with the upper and lower bounds
representing the maximum and minimum reductions, respectively, under varying assumptions of pre-existing immunity in individuals aged $53 (i.e.,
30%, 50%, or 70%). Details of the different vaccination strategies (AR, Outcome, High risk/AR, High risk/Outcome) are outlined in the Methods.
doi:10.1371/journal.pone.0010520.g005
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hospitalization rates, due to both the low frequency of occurrence
of these outcomes and reporting biases and other limitations
inherent in surveillance data, we have focused our analysis on
qualitative results. We have also included alternate estimates of
these outcomes (derived from the U.S. population).
In summary, we have developed an age-structured mathemat-
ical model to evaluate optimal vaccination strategies for pH1N1.
This model demonstrates the importance of the interaction
between pH1N1 transmission dynamics and the demographic
characteristics of population at risk of pH1N1 infection on the
potential effectiveness of vaccination strategies. It also highlights
the value of moving away from strictly age-based vaccination
prioritization schemes toward strategies that target high-risk
groups, regardless of age.
Supporting Information
File S1 Mathematical model details
Found at: doi:10.1371/journal.pone.0010520.s001 (0.30 MB
PDF)
Figure S1 Percent reduction in attack rate, hospitalizations,
ICU admissions, and total deaths, relative to no vaccination,
assuming different program roll-out lengths. Outcomes were
assessed assuming that time to administration of a single dose of
vaccine to all age groups was 2, 4, or 6 weeks, with vaccination
campaigns commencing on November 15, 2009. Estimates are
pooled across vaccination strategy used (attack rate- and outcome-
based), vaccination coverage (base case and upper bound), and
levels of pre-existing immunity in individuals aged $53 (30%,
50%, and 70%) and are shown by month of epidemic peak.
Found at: doi:10.1371/journal.pone.0010520.s002 (0.50 MB TIF)
Figure S2 Impact of a single dose vaccination schedule on
percent reduction in attack rate, hospitalizations, ICU admissions,
and total deaths, relative to no vaccination. The effectiveness of
different strategies was evaluated assuming an epidemic peak in (A)
November, 2009 or (B) January, 2010. Results for October, 2009
and December, 2009 were similar to November, 2009 and
January, 2010, respectively, and are not shown. Vaccination
campaigns began on November 15, 2009, with vaccine conferring
a protective effect immediately after administration of a single
dose. The impact of vaccination coverage is also shown, with base
case rates representing the lower bound of vaccine uptake in the
Canadian population, compared to likely upper limits of vaccine
uptake. The midpoint of the boxes represents the median percent
reduction in the outcome of interest, with the upper and lower
bounds representing the maximum and minimum reductions,
respectively, under varying assumptions of pre-existing immunity
in individuals aged $53 (i.e., 30%, 50%, or 70%). Details of the
different vaccination strategies (AR, Outcome, High risk/AR,
High risk/Outcome) are outlined in the Methods.
Found at: doi:10.1371/journal.pone.0010520.s003 (0.67 MB TIF)
Figure S3 Impact of limited vaccine supply on percent reduction
in attack rate, hospitalizations, ICU admissions, and death,
relative to no vaccination. The effectiveness of different strategies
was evaluated assuming an epidemic peak in November, 2009 or
January, 2010, with vaccination campaigns initiated on November
15, 2009. Results for October, 2009 and December, 2009 were
similar to November, 2009 and January, 2010, respectively, and
are not shown. Enough vaccine was available to vaccinate six
million individuals, with an equal number of doses available each
week of the campaign. The midpoint of the boxes represents the
median percent reduction in the outcome of interest, with the
upper and lower bounds representing the maximum and
minimum reductions, respectively, under varying assumptions of
pre-existing immunity in individuals aged $53 (i.e., 30%, 50%, or
70%). Details of the different vaccination strategies (AR, Outcome,
High risk/AR, High risk/Outcome) are outlined in the Methods.
Found at: doi:10.1371/journal.pone.0010520.s004 (0.52 MB TIF)
Figure S4 Comparison of effectiveness of attack rate- and
outcome-based strategies using alternate estimates of hospitaliza-
tion, ICU admission, and mortality. Percent reduction in
outcomes relative to no vaccination was evaluated assuming an
epidemic peak in (A) November, 2009 or (B) January, 2010, with
vaccination campaigns initiated on November 15, 2009. Resultsfor
October, 2009 and December, 2009 were similar to November,
2009 and January, 2010, respectively, and are not shown. The
impact of vaccination coverage is also shown, with base case rates
representing the lower bound of vaccine uptake in the Canadian
population, compared to likely upper limits of vaccine uptake. The
midpoint of the boxes represents the median percent reduction in
the outcome of interest, with the upper and lower bounds
representing the maximum and minimum reductions, respectively,
under varying assumptions of pre-existing immunity in individuals
aged $53 (i.e., 30%, 50%, or 70%). Details of the vaccination
strategies are outlined in the Methods.
Found at: doi:10.1371/journal.pone.0010520.s005 (0.76 MB TIF)
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